Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris (Nasdaq: VTRS), a global healthcare company, has announced its participation in the BofA Securities 2025 Healthcare Conference in Las Vegas. The presentation is scheduled for Tuesday, May 13, 2025, at 5 p.m. PT / 8 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available for -time viewing at the same location following the live event.
Viatris (VTRS) has filed supplemental New Drug Applications with Japan's Ministry of Health, Labor and Welfare for EFFEXOR® to treat adults with generalized anxiety disorder (GAD). The application follows successful Phase 3 trials where the drug demonstrated superiority over placebo in anxiolytic effects, meeting all seven secondary efficacy endpoints.
The filing aims to introduce the first approved GAD treatment option in Japan, where an estimated 2.6% of the population experiences GAD in their lifetime, with recent studies suggesting a prevalence rate of 7.6%. EFFEXOR®, a serotonin-noradrenaline reuptake inhibitor (SNRI), is already approved for major depressive disorder in Japan and for GAD treatment in over 80 countries globally.
Viatris Inc. (VTRS) has appointed Hemanth J. Varghese as Chief Strategy Officer, joining the Company's Executive Leadership Team. Varghese brings over 20 years of experience in strategy, operations, and corporate development within healthcare companies.
Prior to this appointment, Varghese served as President and COO at Venus Concept, SVP of Strategy & Operations at HLS Therapeutics, and held executive positions at Endo International, Valeant Pharmaceuticals, and Bausch & Lomb. He holds a bachelor's degree and Ph.D. in medical biophysics from the University of Western Ontario and is a Chartered Financial Analyst.
CEO Scott A. Smith expressed confidence that Varghese's expertise will be important for Viatris's growth strategy in 2026 and beyond.
Viatris (VTRS) has announced a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes. The settlement, which does not admit wrongdoing or liability, requires the company to pay up to $335 million over nine years, with annual payments ranging between $27.5 and $40 million.
The company had previously accounted for this potential settlement in its 2024 Form 10-K. Viatris, which has a minimal presence in the U.S. opioids market, manufactures generic versions of naloxone (overdose reversal drug) and buprenorphine/naloxone (opioid addiction treatment). The company is also developing a novel delivery system for meloxicam, a non-opioid pain medication.
Viatris (NASDAQ: VTRS) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. ET on the same day to discuss the quarterly performance.
Interested investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website.
Viatris (NASDAQ: VTRS) has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL. The healthcare company will conduct a fireside chat on Tuesday, March 11, 2025 at 2 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through investor.viatris.com. An archived version will also be available at the same location for a time following the event.
Viatris (VTRS) reported its Q4 and full-year 2024 results, meeting guidance for revenues, adjusted EBITDA, and EPS while exceeding free cash flow targets. The company achieved $14.7 billion in total revenues, with a U.S. GAAP net loss of $(634) million and adjusted EBITDA of $4.7 billion.
Key highlights include $582 million in new product revenues, $825 million returned to shareholders, and $3.7 billion in debt repayment. The company faces challenges with its Indore facility, expecting a negative impact of ~$500 million on 2025 revenues and ~$385 million on adjusted EBITDA due to FDA warning letter and import alert.
For 2025, Viatris plans to prioritize capital return with $500-650 million in share repurchases and expects six Phase 3 data readouts for key assets including selatogrel, cenerimod, and sotagliflozin.
Viatris (NASDAQ: VTRS) has announced its dividend policy for 2025, maintaining an annual dividend of $0.48 per share. The company's Board of Directors has declared a quarterly dividend of $0.12 per share, payable on March 18, 2025, to shareholders of record as of March 10, 2025. This represents the company's fifth consecutive year of dividend payments, demonstrating continued commitment to shareholder returns.
Viatris Inc. (NASDAQ: VTRS) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The company will host a webcast at 8:30 a.m. ET on the same day to discuss the results. Investors and the public can access the live webcast through investor.viatris.com or by calling 844.308.3344 (US) or 412.317.1896 (international). A replay of the webcast will be made available on the company's website.
Viatris Inc. (NASDAQ: VTRS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's presentation and fireside chat are scheduled for Tuesday, January 14, 2025, at 8:15 a.m. PT / 11:15 a.m. ET.
Investors and interested parties can access a live webcast of the event through investor.viatris.com. An archived version of the presentation will be made available at the same location for a time following the live event.
